Tel: 1-631-504-6093
Awesome Features1111

From the Blog

BTK inhibitor Velexbru approved new indications: treatment of two kinds of malignant lymphoma, the total remission rate is 90%

Ono Pharmaceutical recently announced that its BTK inhibitor Velexbru (tirabrutinib hydrochloride, 80mg tablet) has been approved in Japan for the treatment of Fahrenheit macroglobulinemia (WM) and lymphocytic lymphoma (LPL). Velexbru is a highly […]

Read More →